GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (OTCPK:MDBBF) » Definitions » Net Cash per Share

Medlab Clinical (Medlab Clinical) Net Cash per Share : $-0.23 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Medlab Clinical Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Medlab Clinical's Net Cash per Share for the quarter that ended in Dec. 2023 was $-0.23.

The historical rank and industry rank for Medlab Clinical's Net Cash per Share or its related term are showing as below:

During the past 8 years, the highest Price-to-Net-Cash Ratio of Medlab Clinical was 837.86. The lowest was 5.09. And the median was 12.30.

MDBBF's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 3.955
* Ranked among companies with meaningful Price-to-Net-Cash only.

Medlab Clinical Net Cash per Share Historical Data

The historical data trend for Medlab Clinical's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical Net Cash per Share Chart

Medlab Clinical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Cash per Share
Get a 7-Day Free Trial 3.10 1.03 2.66 0.59 -0.48

Medlab Clinical Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.28 0.59 -0.14 -0.48 -0.23

Competitive Comparison of Medlab Clinical's Net Cash per Share

For the Biotechnology subindustry, Medlab Clinical's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medlab Clinical's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's Price-to-Net-Cash falls into.



Medlab Clinical Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Medlab Clinical's Net Cash per Share for the fiscal year that ended in Jun. 2023 is calculated as

Net Cash per Share (A: Jun. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.152-1.251-0)/2.2835
=-0.48

Medlab Clinical's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.205-0.722-0)/2.2835
=-0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medlab Clinical  (OTCPK:MDBBF) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Medlab Clinical Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlab Clinical (Medlab Clinical) Business Description

Traded in Other Exchanges
N/A
Address
11 Lord Street, Unit 5, Botany, NSW, AUS, 2019
Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.

Medlab Clinical (Medlab Clinical) Headlines